Today's Pharma Pulse
Ona lands $86.6M Series B, one of Spain’s biggest biotech rounds
Spanish biotech firm Ona announced an $86.6 million Series B financing, ranking among the largest venture rounds in Spain’s life‑science sector this year. The round was led by Seventure Partners with participation from existing backers and new strategic investors. The funding will be used to scale Ona’s AI‑driven drug discovery platform and accelerate its pre‑clinical programs.
Three‑Month Omega‑3 Trial Cuts Stress and Boosts Sleep in Adults
In a double‑blind trial of 64 adults with high stress, daily omega‑3 capsules for three months produced statistically significant improvements in stress, anxiety, depression, sleep quality and everyday memory. The findings, published in the Journal of Affective Disorders, suggest a readily available nutrient could become a practical tool for mental‑health support.
Engineered Immunosuppressive Dendritic Cells Protect Against Cardiac Remodelling
Researchers engineered fibroblast‑activation‑protein (FAP)‑targeted immunosuppressive dendritic cells (iCDCs) that co‑express CTLA4‑Ig, PD‑L1 and IL‑10. In mouse myocardial infarction, ischemia‑reperfusion and pressure‑overload models, a single iCDC infusion markedly improved ejection fraction, reduced ventricular dilation and fibrosis, and extended survival. The therapy...
Subjective and Neurocognitive Profiling of Clinical Doses of 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Volunteers: Implications for Therapeutic Use
A recent clinical study administered therapeutic doses of MDMA (75‑125 mg) to healthy volunteers and measured both subjective experiences and neurocognitive performance. Participants reported marked increases in empathy, mood elevation, and sociability, with peak effects around 90 minutes and a return to...
What to Watch: FDA's FY 2027 Budget
The FDA’s FY 2027 budget, a $7.2 billion request, outlines several policy‑driven proposals. It seeks new statutory authority to label misleading direct‑to‑consumer drug ads as misbranded, and introduces an optional “Expedited IND” pathway to accelerate Phase 1 trials using validated pre‑clinical data. The...
Novo Nordisk's Explosive Wegovy Pill Launch Draws a New Wave of Patients Into GLP-1 Weight Loss Treatment
Novo Nordisk’s oral Wegovy pill launched in January and has already generated over 600,000 prescriptions within three months, attracting tens of thousands of new patients who previously avoided GLP‑1 injections. The drug is priced at $149‑$299 per month, markedly lower...
University of Arizona Launches $12 Million Rapamycin Clinical Trial
The University of Arizona’s R. Ken Coit College of Pharmacy is launching a double‑blind, randomized Phase 3 clinical trial to test low‑dose rapamycin’s ability to boost resilience and immune function in adults aged 65 and older. The six‑year study, funded by a...
Court Orders FDA To Provide Update On Mifepristone Review Before Midterms
A Louisiana district judge ordered the FDA to issue an update on its Risk Evaluation and Mitigation Strategy (REMS) review for the abortion medication mifepristone within six months. The mandate arrives as the Trump administration faces pressure to clarify its...
Scientists Achieve Major Breakthrough in Safe, Reversible Male Contraception
A multinational research team announced a breakthrough in male contraception: a non‑hormonal, reversible pill that achieved 95% efficacy in Phase‑III trials. The compound, which temporarily blocks sperm maturation, proved safe across a diverse cohort with no reported hormonal side effects....
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Manufacturer-sponsored coupons for biologics have declined from 18.0% of patients in 2017 to 13.9% in 2024, even as the median coupon amount per claim rose from $60 to $90. The drop is most pronounced for obesity and diabetes therapies, while...
Long-Term Cardiac Amyloidosis Survival Benefits Seen in Extension Acoramidis Trial
The open‑label extension of the ATTRibute‑CM trial demonstrated that the transthyretin stabilizer acoramidis (Attruby) delivers sustained survival benefits out to 54 months in patients with cardiac amyloidosis. Participants who began acoramidis early and remained on therapy showed markedly lower all‑cause...
Insmed Discontinues Development of Skin Condition Drug After Mid-Stage Study Miss
Insmed announced it will discontinue development of brensocatib, its investigational therapy for hidradenitis suppurativa, after the drug failed to meet the primary efficacy endpoint in a mid‑stage trial. The study aimed to reduce painful nodules in patients with the chronic...
FDA Approves First Generic Dapagliflozin to Reduce HF Hospitalization Risk in Type 2 Diabetes
The FDA has approved the first generic dapagliflozin tablets, expanding access to the SGLT2 inhibitor that lowers heart‑failure hospitalizations in type‑2 diabetes. The generics match the branded product’s safety and efficacy profile, offering a lower‑cost alternative to Farxiga. This approval...
AlpE Combo: New Tuberculosis Treatment Breakthrough
An international research team has introduced AlpE, a novel combination of Alpibectir and ethionamide, that dramatically shortens tuberculosis therapy and boosts efficacy against drug‑resistant strains. Alpibectir, a new class of mycobacterial enzyme inhibitor, works synergistically with ethionamide to disrupt cell‑wall...
Funding Hurdles Stall Needed Multi‑site BPC‑157 Trial
I can’t see any reason why a proper multi site RCT of BPC157 done by a few independent groups wouldn’t help clarify any real vs placebo effects. The challenge: no one wants to pony up the $ (more like $$$$...
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, adding the FDA‑approved Vykat XR for Prader‑Willi syndrome to its portfolio. The deal also brings together Neurocrine’s existing marketed drugs Ingrezza and Crenessity, which together generated roughly $2.8 billion in 2025 sales....
CRISPR Gene Edit Cuts LDL by 49% in Early Trial, Offering Durable Cholesterol Solution
A CRISPR Therapeutics‑funded study of a single‑dose gene edit that disables the liver gene ANGPTL3 lowered LDL cholesterol by 49% and triglycerides by 55% in a 15‑patient trial. Results published in the New England Journal of Medicine last November have...
What This AI Epitope Library Means for Vaccines, Immunotherapy and Biosensors
CIC biomaGUNE, together with Multiverse Computing, has launched epiGPTope, an AI‑driven platform that designs and classifies synthetic epitopes at scale. The system can generate a library of hundreds of thousands of protein fragments and predict whether they originate from viruses...
Navigating the Frontiers of Advanced Therapeutics and Operational Excellence
In 2026 the biopharma sector is juggling rapid advances in emerging modalities—viral vectors, multispecific antibodies and nucleic‑acid therapies—with heightened operational discipline. Companies are deploying patient‑derived xenograft models, 3‑D organoids and AI‑enhanced spectral flow cytometry to de‑risk next‑gen immunotherapies. Manufacturing focus...
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
The escalating U.S.-Iran conflict is choking key maritime and air routes, slashing global air‑cargo capacity by 22% and threatening the Strait of Hormuz and, potentially, the Bab al‑Mandeb. These chokepoints are vital for transporting active pharmaceutical ingredients (APIs) and finished...
Did Eli Lilly Just Strike Another Gold Mine?
Eli Lilly announced a $1.5 billion acquisition of a biotech portfolio centered on orexin‑targeting therapeutics. The deal adds late‑stage candidates for insomnia, narcolepsy and metabolic disorders to Lilly’s central‑nervous‑system pipeline. Analysts estimate the combined market for orexin drugs could surpass $10 billion by...
Argentina Repeals Pharmaceutical Patent Examination Guidelines
Argentina repealed its 2012 pharmaceutical patent examination guidelines on March 18, 2026, fulfilling commitments under the US‑Argentina Reciprocal Trade and Investment Agreement to harmonize IP standards. The outdated rules had excluded patents on crystalline forms, enantiomers, formulations and other biotech inventions, limiting...
Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.
Novo Nordisk has rolled out Wegovy HD, a 7.2 mg weekly semaglutide injection, across the United States, delivering an average 20.7% weight loss in trials—significantly higher than the 2.4 mg dose. The FDA approved the product in March under its National Priority Review...
Study Suggests $35 Monthly Insulin Cap Has Increased Patient Access
A 2023 Medicare policy capped insulin co‑payments at $35 per month, and a new study shows the limit sharply reduced patients' out‑of‑pocket spending in its first year. Average insulin expenditures fell by roughly 30%, while prescription fill rates climbed, indicating...
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Ascendis Pharma’s Yuviwel (navepegritide) received FDA approval as the first once‑weekly therapy for achondroplasia in children aged two and older. The drug, a TransCon CNP formulation, showed a 1.5 cm greater annual height gain versus placebo in a 52‑week trial and...
Should Clinics Prescribe Medicinal Cannabis that They Also Supply? We Asked 5 Experts
Australian medicinal cannabis prescriptions have exploded, driven by convenient online consultations and one‑stop‑shop models that combine prescribing with dispensing. Critics label this vertical integration a conflict of interest, arguing that clinics may prioritize profit over patient safety and prescribe unapproved...
White House Adds AbbVie's Humira to TrumpRx Alongside Cheaper Biosimilars
The White House’s drug‑discount portal TrumpRx now lists AbbVie’s Humira at $950 per month, a steep cut from its typical $5,000‑plus price. The listing appears alongside two lower‑cost biosimilars that target the same inflammatory conditions. TrumpRx aims to provide seniors...
Newly Developed Smart Molecules Offer a Safer and More Precise Approach to Cancer Care
Researchers at NYU Abu Dhabi have created manganese‑based smart molecules that act as both MRI contrast agents and cancer therapeutics. The compounds stay inert in healthy tissue and activate in the acidic micro‑environment of tumors, releasing manganese ions that enhance...
Outcomes of Treatment for Methicillin-Resistant Staphylococcus Aureus Ventilator-Associated Pneumonia
A retrospective study of 125 patients with MRSA‑associated ventilator‑associated pneumonia compared trimethoprim‑sulfamethoxazole (SMX‑TMP) to the standard vancomycin therapy. Mortality was 28% with SMX‑TMP versus 37% with vancomycin, a difference that was not statistically significant. Clinical cure rates at day 5 and...
Combination of Ranibizumab, Dexamethasone Superior to Ranibizumab Alone for Macular Edema
A retrospective real‑world study of 139 eyes with non‑ischemic retinal vein occlusion‑related macular edema found that sequential ranibizumab followed by a dexamethasone implant yielded superior visual outcomes compared with three monthly ranibizumab injections alone. At three months, the combination group...
Parkinson's Disease
Recent preclinical and early clinical studies explore a range of nutraceuticals and repurposed drugs that target oxidative stress, metal homeostasis, and gut integrity in Parkinson’s disease. Benfotiamine combined with methylcobalamin showed symptomatic improvement in a case series and activates Nrf2...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Researchers at Westlake University unveiled a high‑throughput yeast‑surface‑display platform to engineer fast‑acting covalent protein therapeutics. The system screens diverse crosslinkers and millions of protein variants, enabling precise spatial positioning of warheads that dramatically speeds covalent bond formation. Using the platform,...
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities
U.S. drugmaker Gilead Sciences announced a definitive agreement to acquire German ADC specialist Tubulis for up to $5 billion, including $3.15 billion upfront cash and up to $1.85 billion in milestones. The acquisition brings Tubulis’ next‑generation antibody‑drug conjugate platform, highlighted by the TUB‑040...
Pulsed Intra-Arterial Infusion with Synchronously Controlled Blood Flow: A Novel Strategy for Optimizing Intra-Arterial Chemotherapy
Researchers introduced a pulsed intra‑arterial infusion technique with synchronized blood‑flow control (PBC‑IA) to improve chemotherapy delivery. In rabbit models, the method produced more than 20‑fold higher doxorubicin concentrations in the target gastrocnemius muscle compared with standard intravenous injection, while heart...
DTC Affiliate Marketing Shifts to GLP‑1s Amid Pharma Proxy War
Look, I'd be lying if I said this was the first (or second or fiftieth) MEDVi article. But this is about more than MEDVi or even all the spam, grey zone marketing, and Succession-level drama of business partners acquired by...
Hair‑Loss Pill Redefines Masculinity and Aging
The Hair-Loss Drug Rewriting the Rules of Masculinity A pill to cure baldness is changing the way men age — and how they see themselves. https://t.co/4OiLpmOwGR https://t.co/YQLBx61gVT
Gilead Buys Tubulis to Boost ADC Platform
Gilead Sciences announced a definitive agreement to acquire Germany‑based Tubulis for up to $5 billion, adding a clinical‑stage antibody‑drug conjugate (ADC) pipeline and a next‑generation linker‑payload platform. The deal brings Tubulis’ lead candidate TUB‑040, a NaPi2b‑targeting ADC in phase 1b/2 for platinum‑resistant...
New Cytotoxic Targets Unveiled at AACR26
Time to head off the beaten track at #AACR26 with our latest preview exploring novel targets and cytotoxics. The long climb up the hill may be worth it for some of them: https://t.co/l9tkdWvpuF https://t.co/M5B3RTW1wf
Blueprint for Integrating Psilocybin Into NHS Mental Health Care
British Journal of Psychiatry Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin https://t.co/6sgfqg66rt
Terns Rebuffed a Higher Bid Before Selling to Merck
Terns Pharmaceuticals accepted Merck & Co.'s $53‑per‑share, $6.7 billion buyout, a price roughly 15% below an earlier $61 offer from an unnamed Party C. Party C’s proposal included a contingent $9‑per‑share payout tied to FDA approval of TERN‑701, but it withdrew after updated...
First Human Trial Tests Cellular Age Reversal Therapy
This method to reverse cellular ageing is about to be tested in humans A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely refresh aged tissues and organs. 💡"Technologies to refresh ageing tissue...
Cash‑pay Market for $950 Humira Doubtful vs Cheap Biosimilars
Is there really a cash-pay market for a $950/month brand-name Humira? (...especially w/two adalimumab biosimilars priced at less than $300/mo. already on TrumpRx, and many insured folks paying $0-5/month) https://t.co/taeQUY6Rve
Semaglutide Improves Kidney, Survival Outcomes Along CKD Spectrum
Semaglutide (Ozempic) significantly lowered the risk of kidney failure and all‑cause mortality in the FLOW trial, which enrolled 3,533 type‑2 diabetes patients with chronic kidney disease. The drug reduced the primary composite kidney outcome by 24% (HR 0.76) and cut overall...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash
Neurocrine Biosciences announced a definitive agreement to purchase Soleno Therapeutics for $53 per share, a $2.9 billion cash deal that represents a 34% premium. The acquisition adds Vykat XR, the only FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, to Neurocrine’s rare‑disease portfolio....
Telix Pharmaceuticals Posts 24% Revenue Rise, Shares Jump 5%
Telix Pharmaceuticals announced first‑quarter revenue of $230 million, up 24% year‑over‑year, and reaffirmed its full‑year 2026 guidance of $950‑$970 million. The earnings beat lifted the Nasdaq‑listed stock about 5% in trading, underscoring growing investor confidence in the company’s precision‑medicine platform.
Regulatory Actions for April 7, 2026
On April 7, 2026 regulators issued several high‑profile decisions across biopharma and medical‑technology. Allevion secured FDA clearance for its next‑generation gene‑therapy platform, Regeneron obtained EMA approval for a monoclonal antibody targeting a rare autoimmune disorder, and Stereotaxis earned a CE...
Kennedy Sidestepping Court Order Sidelining ACIP?
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
Gilead Buying Tubulis and Its ADCs in $5B Takeover Bid
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu Wins $5.2M ARPA-H Grant for Ultrasound-Activated Therapeutics
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Other News to Note for April 7, 2026
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
Best of BioWorld: Q1
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...